

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 05-981-H5; EX03-086C-US)

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Confirmation No. 8814

International Filing Date: November 24, 2003

For: CCT6S As Modifiers of the RB Pathway

International App. No.: PCT/US03/037548

and Methods of Use

U.S. Serial No.: 10/535.447

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In the Application of:

Albert K. Tai et al.

Dear Sir:

In regard to the above identified application,

- We are transmitting herewith the attached:
 - a) Information Disclosure Statement (2 Sheets);
 - b) PTO/SB/08b (3 Sheets);
 - c) Copies of Cited References; and
 - Return receipt postcard.
- With respect to fees:
 - a) No fee is believed to be due at this time.
 - Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3.	CERTIFICATE O	F MAIL	ING UND	DER 37	CFR §	1.8: The	undersi	gned he	ereby c	ertifies	that	this
	Transmittal Let	ter and	d the pap	er, as	describe	d in para	graph 1	, are be	eing de _l	posited	via F	irst
	Class Mail wit	h the	United	States	Postal	Service,	in an	envelo	pe ado	dressed	to	the
	Commissioner	for	Patents	, P.O.	Box	1450,	Alexan	dria, ۱	VA 22	2313-14	50	on
	1201.14	20	006.									

Respectfully submitted,

Sherri L. Oslick, Ph.D. Date: <u>204</u>.14 2006

Reg. No. 52,087

2/2

NOV 17 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 05-981-H5; EX03-086C-US)

In the Application of:

Albert K. Tai et al.

International App. No.: PCT/US03/037548

U.S. Serial No.: 10/535,447

International Filing Date: November 24, 2003

For: CCT6S As Modifiers of the RB Pathway and Methods of Use

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Confirmation No. 8814

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form SB/08b. This Information Disclosure Statement is being submitted prior to the issuance of the first Office Action. As such, no fee is due.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

U.S. Documents

U.S. Patent Application No. 6,071,715, applicant Qian et al., published June 6, 2000.

Foreign Documents

- 2. PCT Patent Publication No. WO 97/41433, published November 6, 1997.
- 3. PCT Patent Publication No. WO 99/41376, published August 19, 1999.

Other Documents

- Li Wen-Zhuo et al: "Tcp20, a subunit of the eukaryotic TRiC chaperonin from humans and yeast" Journal of Biological Chemistry, Vol. 269, No. 28, 1994, pages 18616-18622, XP002394303.
- Kubota Hiroshi et al.: "Structures and co-regulated expression of the genese encoding mouse cytosolic chaperonin CCT subunits", European Journal of Biochemistry, Vol. 262, No. 2, June 1999 (1996-06), pages 492-500, XP002394304.
- Feldman Douglas E. et al.: "Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRIC" Molecular Cell, Vol. 4, No. 6, December 1999 (1999-12), pages 1051-1061, XP002394305.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the documents cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-SB/08b) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO/SB/08b. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Bv:

Respectfully submitted.

Date: _1001.14 , 2006

Sherri L. Oslick, Ph.D.

Reg. No. 52,087

McDonnell, Boehnen Hulbert & Berghoff

300 South Wacker Drive Chicago, IL 60606 aperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

e for form 1449A/PTO

l 1 Sheet

PTO/SB/08a (09-06) Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

NFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete If Known						
Application Number	10/535,447					
Filing Date	May 19,2005					
First Named Inventor	Albert K. Tai					
Art Unit	N/A					
Examiner Name	N/A					
Attorney Docket Number	05-981-H5	\neg				

11 0	DATE	NIT DOCUMENTO

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No.1	Number-Kind Code ^{2 (f known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	A1	us-6,071,715	06-06-2000	Qian et al.	
		US-			
-		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°
	A2	WO 97/41433	11-6-1997	Cancer Research Campaign Technology Limited		
	A3	WO 99/41376	08-19-1999	Curagen Corporation		
	F					

$\overline{}$		
Examiner	Date	
Signature	Considered	
C-	90110100100	1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicants unique citation designation number (ciptorial). "See Kinds Godes of USP10 Father Office of the Comments at wave upgate agree of MPEP 901.04. "Either Office that issued the document, by the whether code (VMPO Standard ST.3)." For Judicials patient document, his indication of the year of the reign of the Emperor must procede the serial number of the patient document. "Nind of occurrent by the appropriate symbols as indicated on the document unique WMPO Standard ST. 16 if possible." Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form amount suggestions for reducing this outcome, should be sent to the chief instance of the sent suggestions of reducing this outcome, should be sent to the chief instance of the sent suggestions of reducing this outcome, should be sent to the chief instance of the sent suggestions of reducing this outcome, should be sent to the chief instance of the sent suggestions of reducing this outcome, should be sent to the sent suggestion of the sent suggestions of reducing this outcome, should be sent to the sent suggestion of the sent suggestion of the sent suggestions of the

PTO/SB/08h (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Subs	titute for form 1449B/PTO				Complete if Known	
				Application Number	10/535,447	
IN	FORMATION DIS	CLOS	URE	Filing Date	May 19, 2005	
STATEMENT BY APPLICANT			ANT	First Named Inventor	Albert K. Tai	
				Art Unit	N/A	
(Use as many sheets as necessary)				Examiner Name	N/A	
Sheet	2	of	3	Attorney Docket Number	05-981-H5	

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²					
	A4	LI Wen-Zhuo et al: "Tcp20, a subunit of the eukaryotic TRiC chaperonin from humans and yeast" Journal of Biological Chemistry, Vol. 269, No. 28, 1994, pages 18616-18622, XP002394303.						
	A5	Kubota Hiroshi et al.: "Structures and co-regulated expression of the genese encoding mouse cytosolic chaperonin CCT subunits", European Journal of Biochemistry, Vol. 262, No. 2, June 1999 (1996-06), pages 492-500, XP002394304.						
	A6	Feldman Douglas E. et al.: "Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC" Molecular Cell, Vol. 4, No. 6, December 1999 (1999-112), pages 1051-1061, XP002394305.						
	\vdash							

Examiner Signature	/Misook Yu/	Date Considered	04/19/2009

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINER: Intils if reference considered, whether or not citation is in contomance with network. Draw me immugin citation is not in contomance with network process of the control of the considered include copy of this form with net accommunication to applicant.

Applicant's unique citation designation number (optional). *Applicant's to place a check mark here if English language Translation is submitted in the internation is required by 37 CPR 137 and 188. The information is required to obtain or retain a benefit by the public which is to file (and by the Language process) an application. Confidentially is governed by 35 U.S. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to compete, or the process of the process of the confidentially is governed by 35 U.S. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to compete the process of the confidentially is governed by 35 U.S. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to compete the confidential of the process of the confidential to the confiden ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that; (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator. General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.